ArticleThe Journal of biological chemistry2026
Metabolic flexibility and an unusual route for peptidoglycan muramic acid recycling in mycobacteria.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
De novo biosynthesis of cell wall peptidoglycan is essential for bacterial viability under many growth conditions and is a well-validated antibiotic target. Although generally not essential for bacterial fitness under standard laboratory growth conditions, peptidoglycan recycling can aid bacterial survival under host or antibiotic stress. Peptidoglycan consists of alternating sugars N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) cross-linked by peptides. Recycling of these sugars can proceed via GlcNAc and glucosamine intermediates (Escherichia coli-type) or, in the case of MurNAc, bypass these intermediates altogether (Pseudomonas-type). We serendipitously discovered that the pathogen Mycobacterium tuberculosis and model organism Mycobacterium smegmatis assimilate MurNAc probes into their peptidoglycan despite lacking the Pseudomonas-type machinery that is normally required for incorporation of these molecules. Our data suggest that muramic acids can incorporate into M. smegmatis peptidoglycan via multiple pathways: an E. coli-type route and a non-E. coli, non-Pseudomonas-type route with GlcNAc but not glucosamine intermediates. These findings reveal metabolic flexibility in mycobacterial cell wall recycling that encompasses a previously undescribed pathway.
Indexed as
Identifiers
42759660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.